Decentralized Clinical Trials (DCTs): Operational Challenges, Compliance and Patient Safety for CROs

Reading time: 6 minuti

Decentralized Clinical Trials (DCTs) are reshaping the operational model of modern clinical research by shifting study activities closer to patients. This evolution introduces new opportunities in terms of accessibility, efficiency, and patient engagement, but also significant operational and regulatory complexity. Understanding how to balance innovation with compliance, patient safety, and data integrity is now a central priority for sponsors and CROs.

 

THE EVOLVING LANDSCAPE OF DECENTRALIZED CLINICAL TRIAL

Decentralized Clinical Trials (DCTs) are becoming an increasingly important model in modern clinical research. By integrating patient-centric approaches, home healthcare services, telemedicine, wearable devices, electronic patient-reported outcomes (ePROs), and direct-to-patient solutions, DCTs enable sponsors and Clinical Research Organizations (CROs) to conduct clinical trials beyond the traditional site-based setting¹.

Decentralized and hybrid clinical trial models gained significant momentum during the COVID-19 pandemic, when sponsors and CROs were required to preserve recruitment, ensure continuity, and maintain patient access despite major disruptions to site-based research. Since then, DCTs have progressively evolved from emergency-driven adaptations into structured and scalable operating models aimed at reducing patient burden, improving recruitment and retention, and enabling a more patient-centric trial experience².

Recent literature indicates that DCTs may enhance inclusivity, accessibility, and operational flexibility, particularly by overcoming geographical barriers, limited participant diversity, and logistical constraints through remote technologies and community-based providers³. At the same time, emerging evidence highlights that their long-term sustainability depends on the ability to address persistent challenges related to data integrity, technology performance, and regulatory compliance.

A recent analysis of 1,370 decentralized trials registered on ClinicalTrials.gov describes a rapidly expanding but still heterogeneous landscape, where behavioral interventions appear particularly suitable for decentralization. The analysis also notes that many studies focus on evaluating decentralized methodologies rather than solely implementing them. In addition, highly digitalized DCT models remain primarily concentrated in high-income countries, although global adoption is steadily increasing⁴.

The adoption of decentralized and hybrid clinical trial models has accelerated significantly in recent years, particularly in studies involving geographically dispersed populations and participants with limited access to investigational sites. European regulators acknowledge the value of DCTs, while emphasizing that patient safety, data integrity, and investigator oversight must remain equivalent to those required in conventional clinical trials⁵.

While the benefits of DCTs are widely recognized, their effective implementation depends on the ability to manage a series of operational, logistical, and regulatory challenges. For CROs, selecting operational partners capable of integrating seamlessly into established governance frameworks is essential to ensure compliance and consistent execution across all decentralized activities.

OPERATIONAL CHALLENGES IN DECENTRALIZED CLINICAL TRIAL MANAGEMENT

As trial-related activities increasingly move closer to the patient’s home, sponsors and CROs must ensure that compliance, quality standards, and operational oversight remain consistent throughout the study. The most relevant challenges associated with decentralized clinical trials include:

  • Investigator oversight and regulatory compliance
  • Patient safety in home-based clinical trial activities
  • Data integrity and quality management
  • Clinical trial logistics and service provider coordination⁵–⁹

INVESTIGATOR OVERSIGHT AND REGULATORY COMPLIANCE

One of the most frequently discussed challenges in DCTs is maintaining adequate investigator oversight.

In traditional clinical trials, investigators directly interact with participants through scheduled site visits and in-person assessments. In decentralized models, however, several trial-related activities—such as home healthcare visits, laboratory testing, logistics management, and digital platform operations—may be performed by external service providers⁵˒⁶.

This expanded operational ecosystem requires clearly defined roles, responsibilities, and supervision mechanisms. European regulatory guidance emphasizes that decentralized activities should be regarded as an extension of the clinical trial site rather than a replacement. Investigators must retain full oversight of participant safety, protocol adherence, and all study-related decisions throughout the trial⁵.

PATIENT SAFETY BEYOND THE CLINICAL SITE

Patient-centricity is a key driver of decentralized clinical trials. However, shifting study procedures outside traditional investigational sites introduces additional considerations for participant protection.

Home healthcare visits, remote assessments, biological sample collection, and home administration of investigational medicinal products (IMPs), defined as medicinal products under clinical investigation and not yet authorized for commercial use, require robust safety frameworks. These include adverse event reporting systems, emergency communication pathways, and appropriately trained healthcare professionals⁵˒⁶.

Unlike marketed therapies, IMPs may have safety profiles that are not yet fully characterized, requiring enhanced monitoring and comprehensive risk management procedures when administered outside controlled clinical environments⁵.

Regulators consistently emphasize that decentralization must not compromise participants’ rights, safety, dignity, or well-being. Ensuring equivalent standards of care outside traditional clinical settings remains one of the central challenges in DCT implementation⁵˒⁶.

Effective patient engagement and clear communication are also essential to support adherence, retention, and overall study success⁵.

DATA INTEGRITY AND QUALITY MANAGEMENT

The increasing use of digital technologies has transformed clinical trial data collection and monitoring. Wearable devices, ePRO platforms, and remote monitoring tools enable more frequent and continuous data capture in real-world settings¹.

However, this increased data availability introduces additional operational complexity. Sponsors and CROs must address challenges related to source data verification, system validation, interoperability, cybersecurity, GDPR compliance, and data volume management⁵˒⁶.

Recent analyses indicate that, despite strong interest in decentralized approaches, concerns regarding data reliability, technological performance, and operational consistency remain significant barriers to broader adoption. The long-term success of DCTs depends not only on technological innovation but also on the robustness of the underlying operational frameworks⁶.

CLINICAL TRIAL LOGISTICS AS A CRITICAL SUCCESS FACTOR

Logistics represents one of the least visible but most critical components of decentralized clinical trial execution. Successful implementation depends on the seamless coordination of direct-to-patient services, biological sample collection and shipment, temperature-controlled transportation, medical device handling, participant scheduling, and communication across multiple stakeholders⁵˒⁷.

Disruptions in these processes can negatively affect protocol compliance, data quality, and study timelines. This complexity becomes even more pronounced in geographically dispersed or vulnerable populations, where logistics plays a strategic role in ensuring continuity, adherence, and operational reliability⁵˒⁷.

Ultimately, the core challenge is not decentralization itself, but the ability to maintain consistent standards of quality, safety, compliance, and patient care outside traditional clinical sites. As decentralized and hybrid models continue to expand, CROs increasingly require partners capable of managing this complexity across diverse healthcare systems and regulatory environments.

SELECTING THE RIGHT PARTNERS FOR DECENTRALIZED CLINICAL TRIALS

For CROs, vendor selection has become a strategic component of decentralized and hybrid trial execution. As trial-related activities extend into patients’ homes, operational partners function as extensions of the clinical trial site and of investigator responsibilities. Therefore, structured and transparent evaluation criteria are essential to ensure patient safety, data integrity, and regulatory compliance.

Five key criteria can support vendor evaluation in decentralized and hybrid models:

  1. Vendor know-how and expertise
    Assessment should include experience in managing complex homecare operations within clinical research, including rare diseases, high-risk therapies, and vulnerable populations. Relevant indicators include prior study experience, familiarity with local healthcare systems, and adherence to GCP and national regulations.
  2. Homecare performance and service standards
    Evaluation should consider the size and reliability of the home nursing network, geographic coverage, protocol adherence, response times, patient engagement practices, and the availability of measurable KPIs. Evidence of historical performance and contingency planning capabilities is essential.
  3. Interoperability across services
    In decentralized settings, homecare, digital platforms, and logistics systems must operate as an integrated ecosystem. Vendors should demonstrate the ability to coordinate securely with ePRO systems, wearable technologies, central laboratories, logistics providers, and other study stakeholders, ensuring GDPR-compliant and real-time data exchange.
  4. Ecosystem relationships
    Vendors should be assessed based on their ability to operate within broader healthcare networks. Existing relationships with investigators, pharmacists, laboratories, general practitioners, and other local stakeholders can significantly impact feasibility, execution efficiency, and patient support.
  5. Compliance framework
    A robust GxP-oriented quality system is essential, including documented SOPs, training records, risk management procedures, deviation handling processes, and clearly defined accountability structures. Compliance should be evaluated as an operational capability embedded in day-to-day execution rather than a purely formal requirement.

CONCLUSION: OPERATIONALIZING DECENTRALIZATION

Applying structured evaluation criteria enables CROs to identify partners capable not only of delivering isolated services, but of functioning as reliable operational extensions of the clinical trial site. In decentralized models, this capability is fundamental to ensuring consistency across patient-facing activities, data flows, logistics operations, and stakeholder coordination.

Effective implementation of DCTs requires more than technological enablement. It depends on operational expertise, standardized processes, and consistent execution across all decentralized components. In this context, experienced service providers with established healthcare networks and capabilities in home-based clinical operations play a key role in supporting study delivery.

Such capabilities typically include:

  • Home healthcare and biological sample collection services
  • Direct-to-patient and direct-from-patient services
  • Patient concierge services
  • Operational support for decentralized and hybrid clinical trials

By combining qualified healthcare professionals, standardized operational processes, and local healthcare system knowledge, experienced partners contribute to more efficient, compliant, and patient-centered execution of decentralized and hybrid clinical trials.

 

 

REFERENCES

  1. de Jong AJ, van Rijssel TI, Zuidgeest MGP, van Thiel GJMW, Askin S, Fons-Martínez J, De Smedt T, de Boer A, Santa-Ana-Tellez Y, Gardarsdottir H; Trials@Home Consortium. Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective. Clin Pharmacol Ther. 2022 Aug;112(2):344-352.
  2. Heras BDL, Daehnke A, Saini K, Harris M, Morrison K, Aguilo A, et al. Role of decentralized clinical trials in cancer drug development: Results from a survey of oncologists and patients. Digital Health. 2022.
  3. Jean-Louis G, Seixas AA. The value of decentralized clinical trials: Inclusion, accessibility, and innovation. 2024 Aug 22.
  4. Kijewski S, McBride C, Owens E, Bernheim E, Vayena E. Decentralized clinical trials: A comprehensive analysis of trends, technologies, and global challenges. PLOS Digital Health. 2026.
  5. European Medicines Agency (EMA), Heads of Medicines Agencies (HMA), European Commission. Recommendation Paper on Decentralised Elements in Clinical Trials. Version 02. Amsterdam: EMA; 2025.
  6. Jiang Y, Leng Y, Wu Q, Hou Y, Dong X, Zeng C, Wu D, Fang H, Tang Y, Huang H, Li N. Understanding the gap between expectations and reality in decentralized clinical trials. NPJ Digit Med. 2025 Jul 4;8(1):408.
  7. Top 10 Challenges and Solutions for Decentralized Clinical Trials: Technology, Diversity and Regulations in 2025 and Beyond. DIA Global Forum. March 2025.
  8. Heras BDL, Daehnke A, Saini K, Harris M, Morrison K, Aguilo A, et al. Role of decentralized clinical trials in cancer drug development: Results from a survey of oncologists and patients. Digital Health. 2022.
  9. Biswas A, Dalal J. Decentralized clinical trials-balancing promise and pitfalls in modern research: a systematic review. International Journal of Clinical Trials. 2025.